Webinar: Formulation and Manufacturing Approaches for Nasal Drug Products

In this webinar, David Ward, Intertek’s Formulation/Manufacturing Lead, presented an introduction to the formulation and manufacturing approaches for nasal drug products including; solubility experiments, excipient selection, device selection / screening, formulation processes and batch scale up.

Like Comment

Webinar: Formulation and Manufacturing Approaches for Nasal Drug Products

The inhaled product class includes a diverse group of products including Pressurized Metered Dose Inhalers (pMDI) which can exist in solution or suspension form with a range of different propellants, Dry Powder Inhalers (DPI) which can include multi-unit dose blister devices, capsule-based devices or reservoir products. Strategic formulation and manufacturing approaches for nasal sprays must be adapted to the drug/device in question to ensure successful development.

Access the recording now by completing the form below:


Intertek Melbourn

Intertek Melbourn has specialist skills and experience in analytical testing and formulation for both small molecule and biologic orally inhaled and nasal drug products (OINDP), alongside all other pharmaceutical dosage forms. With 30 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support for method development / validation, analytical testing, stability programs, CMC studies, formulation development and clinical manufacturing from our facility located in Melbourn, near Cambridge, UK. Our team of scientists have a reputation for providing outstanding and responsive customer service and we have recently announced a significant expansion to double our laboratory footprint and further increase our capacity and flexibility. Through our expertise in analytical and formulation support for the pharmaceutical, biotechnology and drug delivery industries, we help our clients to meet milestones for their challenging pharmaceutical development programmes. The laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The Laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections. • Method Development / Validation • Analytical Testing • Formulation Development • Device Screening • Quality by Design (QbD) Studies • ICH and Accelerated Stability Studies • Clinical Trials Materials Manufacturing • Product Characterisation Studies • In-Vitro Bioequivalence Studies for Generic Products
4 Contributions
0 Following